• 1. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 2. Evolutionary approaches in protein engineering towards biomaterial construction
  Brindha J.,Balamurali M. M.,Kaushik Chanda RSC Adv., 2019,9, 34720-34734
• 3. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 4. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 5. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409

Introduction to 3,6-Dimethoxy-2-nitropyridine (CAS No. 1806291-13-3)

3,6-Dimethoxy-2-nitropyridine, identified by its Chemical Abstracts Service (CAS) number 1806291-13-3, is a heterocyclic organic compound that has garnered significant attention in the field of chemical biology and pharmaceutical research. This compound belongs to the pyridine family, a class of nitrogen-containing heterocycles that are widely recognized for their diverse biological activities and utility in medicinal chemistry. The structural features of 3,6-Dimethoxy-2-nitropyridine, particularly the presence of methoxy and nitro substituents, contribute to its unique chemical properties and make it a valuable scaffold for the development of novel therapeutic agents.

The molecular structure of 3,6-Dimethoxy-2-nitropyridine consists of a six-membered aromatic ring containing nitrogen, with methoxy groups attached at the 3rd and 6th positions and a nitro group at the 2nd position. This arrangement imparts a balance of electron-donating and electron-withdrawing effects, which can influence its reactivity and interactions with biological targets. The nitro group, in particular, is known to be a versatile functional handle in organic synthesis, enabling further derivatization through reduction or nucleophilic substitution reactions.

In recent years, 3,6-Dimethoxy-2-nitropyridine has been explored as a key intermediate in the synthesis of various biologically active compounds. Its pyridine core is a common motif in many pharmaceuticals, including antiviral, antibacterial, and anticancer agents. The methoxy substituents enhance lipophilicity, while the nitro group can be used to modulate pharmacokinetic properties. This makes 3,6-Dimethoxy-2-nitropyridine a promising building block for drug discovery programs targeting neurological disorders, inflammation, and metabolic diseases.

One of the most compelling aspects of 3,6-Dimethoxy-2-nitropyridine is its potential in medicinal chemistry due to its ability to serve as a precursor for more complex molecules. Researchers have leveraged its structural framework to develop inhibitors of enzymes involved in cancer progression and inflammatory pathways. For instance, derivatives of this compound have shown promise in preclinical studies as modulators of Janus kinases (JAKs), which are implicated in autoimmune diseases such as rheumatoid arthritis. The nitro group can be selectively reduced to an amine, allowing for further functionalization into more sophisticated pharmacophores.

The synthesis of 3,6-Dimethoxy-2-nitropyridine typically involves multi-step organic reactions starting from readily available pyridine derivatives. The introduction of methoxy groups can be achieved through nucleophilic aromatic substitution or metal-catalyzed cross-coupling reactions. Subsequent nitration at the 2-position is commonly performed using classical nitrating agents such as nitric acid in the presence of sulfuric acid. These synthetic routes highlight the compound's accessibility and its suitability for large-scale production.

Recent advances in computational chemistry have further enhanced the utility of 3,6-Dimethoxy-2-nitropyridine in drug design. Molecular modeling studies have revealed that this compound can interact with biological targets through hydrogen bonding networks formed by its nitrogen atoms and oxygen-containing substituents. These interactions are critical for determining binding affinity and selectivity in drug candidates. Additionally, virtual screening techniques have been employed to identify novel analogs of 3,6-Dimethoxy-2-nitropyridine with enhanced pharmacological properties.

The pharmacological profile of 3,6-Dimethoxy-2-nitropyridine has been investigated in various cellular and animal models. Studies have demonstrated its potential as an anti-inflammatory agent by inhibiting pro-inflammatory cytokine production. Furthermore, its ability to modulate neurotransmitter receptors has sparked interest in its role as a potential treatment for neurodegenerative diseases such as Alzheimer's and Parkinson's. These findings underscore the therapeutic relevance of this compound and highlight opportunities for further exploration.

In conclusion,3,6-Dimethoxy-2-nitropyridine (CAS No. 1806291-13-3) represents a significant asset in the pharmaceutical industry due to its versatile structural features and biological activities. Its role as an intermediate in drug synthesis underscores its importance in medicinal chemistry research. As our understanding of disease mechanisms continues to evolve,3,6-Dimethoxy-2-nitropyridine will likely remain at the forefront of efforts to develop innovative therapeutic strategies that address unmet medical needs.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)